Introduction
Gene transfer into haematopoietic stem cells (HSC) represents a potential therapeutic approach for several inherited blood diseases. Until now, recombinant oncoretroviral vectors derived from the murine Moloney leukaemia virus have been used to genetically modify HSC. [1] [2] [3] [4] However, the strong enhancer activity of native Moloney leukaemia virus sequences driving transgene expression in addition to the recently highlighted integration bias of these vectors towards gene regulatory regions near transcriptional start sites 5, 6 are both associated with a major risk of insertional mutagenesis, which may challenge further clinical use of these vectors. 7 Lentiviral vectors, mainly derived from human immunodeficiency virus type 1 (HIV-1), initially held attention by their capacity to transduce quiescent cells; 8, 9 their ability to efficiently transduce HSC is now well demonstrated and proved superior compared to oncoretroviral vectors. 10, 11 Moreover, lentiviral vectors offer more flexibility for inclusion of heterologous sequences like complex regulatory regions that allow tight control of transgene expression throughout haematopoietic differentiation. 12 The efficient removal of most viral-coding sequences and native promoters in selfinactivating vectors leads to significant enhancement of gene transfer safety. 13 Moreover, the risk of triggering oncogenic processes may be lower with lentiviral vectors since they do not target transcription start site for genomic integration as Moloney leukaemia virus vectors. 6, 14 Indeed, HIV-1-derived lentiviral vectors are now moving to the clinic. 15, 16 X-linked agammaglobulinaemia (XLA), or Bruton's disease, is a primary humoral deficiency that stands for about 85% of early B-cell defects. 17 The disease results from an intramedullary block of B-cell differentiation at the pro-B-cell stage that causes agammaglobulinaemia. Mutations of the BTK gene (for Bruton's tyrosine kinase) was linked to XLA in 1993. 18, 19 In mice, absence of functional Btk leads to the X-linked immunodeficiency (Xid) phenotype, which is less severe than human XLA. 20, 21 Current treatment for Bruton's disease is based on regular intravenous Ig injections; it generalized since mid 80s and significantly increased the quality of life for XLA patients. 22 Nevertheless, frequency of severe and handicapping diseases like disseminated enteroviral infections and chronic pulmonary diseases remains high and is still associated with increased morbidity for XLA individuals. 23 As a definitive curative treatment, HSC gene therapy could represent an interesting alternative for XLA patients compared to substitutive intravenous Ig injection therapy. 24 An important step towards XLA gene therapy feasibility by HSC gene transfer was recently achieved in the Btk/Tec À/À murine model using a retroviral vector that ubiquitously expressed the human BTK gene. 25 Nevertheless, XLA gene therapy approval will strictly depend on improvement of risk-benefit ratio compared to standard intravenous Ig injection therapy; especially, risks of serious adverse effects associated with the use of ubiquitous oncoretroviral vector may not be acceptable in the context of Bruton's disease.
We recently developed a lentiviral vector carrying a promoter sequence derived from the human CD19 gene that allows efficient targeting of green fluorescent protein (GFP) transgene expression to the B-lymphoid progeny of genetically modified human CD34+ haematopoietic progenitors. 26 This vector represents an interesting tool for XLA gene therapy; restriction of BTK transgene expression to the B-cell compartment, avoiding potentially detrimental ectopic expression in other lineages, is a rational approach to improve therapeutic safety. 24 Moreover, human CD19 promoter-controlled BTK expression was proved safe and efficient to correct phenotypic defects in transgenic Xid mice. 27 To improve the level of transgene expression, we looked for an enhancer sequence that could act specifically in B cells and increase CD19 promoter transcriptional activity. The Emmar sequence comes from the J H -Cm intronic region of the murine Ig heavy-chain locus where it physiologically acts as a transcriptional enhancer for heavy-chain m gene expression in B cells. 28 It is composed of a central enhancer sequence (Em) flanked by matrix attachment regions, which play a crucial role in sequence functionality. 29 Indeed, matrix attachment regions act both as an enhancer of gene expression in B-lymphoid cells and as a repressor in other haematopoietic lineages and are notably able to locally remodel chromatin structure. 30 These properties result from interactions with activating factors like Bright, 31 the expression which is restricted to B cells, or matrix attachment region-BP1, 32 and inhibiting factors like SATB1, expressed in non-B cells and especially in T cells, 33 or NF-mNR. 34 In the context of recombinant lentiviral vectors carrying the cytomegalovirus or phosphoglycerate kinase (PGK) ubiquitous promoters, Emmar is able to specifically promote strong and position-independent GFP transgene expression in the B-lymphoid lineage. 35 This work describes the development of a suitable gene transfer tool for future XLA gene therapy by improvement of the original CD19 promoter-based lentiviral vector by Emmar sequence addition that allows efficient B-specific expression of the human BTK transgene throughout long-term human haematopoietic differentiation.
Results

B-specific enhancement of GFP expression by Emmar addition
The murine Emmar enhancer sequence was cloned upstream of the human CD19-derived promoter into our previously described B-specific lentiviral vector (Figure 1 ). 26 Three cell lines of B-lymphoid (Nalm6), T-lymphoid (JA-16) and myeloid (U937) origin were transduced with the EF1-GFP ubiquitous lentiviral vector and with L19-GFP or EL19-GFP lentiviral vectors in parallel. As shown by flow cytometry analysis, the new EL19 composite promoter sequence led to strong and B-cell-specific enhancement of GFP expression intensity (MFI, mean fluorescence intensity) compared to the original L19 promoter (Figure 2a ). The MFI per viral copy was about sixfold higher in the B-cell line with EL19 compared to L19 lentiviral vector (Figure 2b ). In addition, intensity of transgene expression was more homogenous inside the GFP-positive cell population when the EL19 promoter was used; this is consistent with the previously described Emmar capacity to allow independent transgene expression from random genomic viral integration sites. 35 Human CD34+ cells from cord blood (CB) (n ¼ 4) or adult bone marrow (BM) (n ¼ 1) were transduced with EL19-GFP lentiviral vector and subjected to in vivo differentiation using the NOD/SCID (Non-Obese Diabetic-Severe Combined Immune Deficiency) murine xenograft model. GFP expression in differentiated human B cells (CD19+) and non-B cells (CD19À) recovered from mouse BM and spleen was measured by flow cytometry. GFP was preferentially expressed in B-lymphoid progeny with 46.9±7.1 and 12.1±3% GFP-positive cells for B and non-B cells respectively (Figure 3a) . Importantly, the percentage of GFP-positive cells from each animal was always higher in B cells (mean ratio of 5.7±1). In addition, the MFI was significantly higher in B cells compared to non-B cells (591 ± 110 vs 66±16 respectively, see Figure 3b ). Results obtained with cells recovered from spleens were similar, though we observed slightly more GFP expression in the non-B-cell population (Figures 3a and b) . Conversely, control transduction of CD34+ cells with the EF1-GFP ubiquitous vector produced homogenous GFP expression in all the progenies (Figure 3c ). Molecular analyses of sorted B-cell and non-B-cell populations showed similar lentiviral transduction efficiencies, which demonstrated that preferential B-lymphoid GFP expression actually came from selective EL19 transcriptional activity in B cells (Figure 3d) . Finally, addition of the Emmar sequence strongly enhanced the transcriptional activity of the L19 Figure S1 and Moreau et al. 26 ). Intensity of transgene expression was even higher in EL19-GFP-transduced B cells compared to control EF1-GFP-transduced cells (591±110 vs 386±79 MFI respectively, Figure 3c ).
EL19 sequence promoter activity through B-lymphoid differentiation steps was then analysed by defining three sub-populations of growing maturity according to CD34
and IgM surface expression within total CD19+ B cells: the early pro-B (CD34+/IgMÀ), pre-B (CD34À/IgMÀ), and immature and mature B-cell (CD34À/IgM+) stages (Figure 3e ). The percentage of GFP-positive cells was stable throughout B-differentiation steps, while intensity of GFP expression went up significantly from pro-B to pre-B cells in BM and remained high in mature splenic B cells ( Figure 3e and Table 1 ). In contrast, percentage of GFP-positive cells and transgene expression intensity was significantly lower in CD34+ immature progenitors (Table 1) . 
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Results from NOD/SCID mice transplanted with transduced CD34+ progenitors showed that transcriptional activity of the composite EL19 sequence was weak in the CD19-negative progeny. This population was mainly composed of CD33+ myeloid cells, in addition to few CD34+ immature progenitors in the BM (data not shown). We also conducted two independent experiments in NOD/SCID/gc null mice 36 that efficiently support thymic T-lymphocyte development. Transcriptional activity of the EL19 sequence was very low in the CD2+ T-cell progeny of CB-or BM-transduced progenitors retrieved from murine thymuses. Indeed, dim GFP expression was detected only in some rare T cells ( Figure  4 ) while they were efficiently transduced ( Figure 3d ). Additional in vitro cultures also showed very low promoter activity of the EL19 sequence in myeloid, dendritic and erythroid lineages differentiated from transduced haematopoietic progenitors (Supplementary Figure S2) .
Efficient human BTK expression with enhanced B-specific lentiviral vectors
We replaced the GFP sequence by the Flag-tagged human BTK (fBTK) into L19-and EL19-GFP vectors ( Figure 1 ).
Haematopoietic cell lines of different origins were transduced in parallel with the L19-and EL19-fBTK lentiviral vectors as well as with the ubiquitous EF1-fBTK vector as positive control. Sixteen days after transduction, transduction efficiency was checked by quantitative PCR on genomic DNA and transgenic fBTK protein expression was analysed by immunoblotting; as expected, fBTK was detected in all cell types when the showed an efficient and preferential fBTK transgene expression in medullary and splenic B-lymphoid progeny: 2.7 ± 0.8 and 1.1 ± 0.3 transgene messengers per endogenous BTK messenger copy were detected, compared to 0.5 ± 0.1 and 0.3 ± 0.0 copies in non-B cells (Figure 6b, experiment 1) .
A second set of experiments (experiments 2-4) was performed with lower lentiviral titres (3 mg p24 per 10 6 cells) to minimize viral genomic integrations. On average, we obtained less than 2 vector copies per cell in differentiated B cells and non-B cells: 1.3 ± 0.3 and 1.4±0.2 copies respectively in BM (Figure 6a ). In these conditions, fBTK messenger expression appeared weak and below the endogenous BTK level when molecular analysis of CD19-sorted populations was used ( Figure  6b ). However, since we were not able to determine transduced cell ratio among sorted cells, such global molecular analysis probably underestimates transgene expression in transduced cells. Eventually, fBTK transgenic protein was efficiently and preferentially detected We analysed human haematopoietic engraftment features after injection of EL19-fBTK-transduced CD34+ progenitors into NOD/SCID mice. Even in high transduction conditions (experiment 1), composition of medullary and splenic human grafts was not modified by fBTK expression; in particular, no significant effect was noticed on B-lymphoid differentiation (Supplementary Figure S3 ).
Discussion
We have developed a B-specific HIV-1-derived lentiviral vector that generates strong preferential long-term transgene expression throughout B-lymphoid differentiation of genetically modified human haematopoietic progenitors. The recombinant expression cassette is based on association of our previously described minimal human CD19-derived promoter 26 with the murine Emmar B-specific enhancer sequence. Several viral vectors targeting transgene expression to the B-cell compartment have been described concomitantly with our work: a Moloney leukaemia virus g-retroviral encompassing a similar human CD19 promoter-derived sequence, 38 lentiviral vectors carrying first a combination of Emmar and ubiquitous promoters, 35 or more recently a minimal promoter derived from the murine Ig-kappa gene associated with 3 0 and 5 0 enhancers from the murine Ig heavy-chain locus (the latter corresponds to the Emmar sequence). 39 However, none of these recombinant vectors have been evaluated for the expression of another transgene than GFP.
Compared to our original vector encompassing the minimal CD19 promoter alone, upstream addition of the Emmar sequence finally results in a 12-fold increase of GFP transgene expression in B-lymphoid cells even with fewer lentiviral integrations per cell. In the meantime, B-preferential expression of the transgene is not impaired; it remains significantly lower to absent in haematopoietic precursors, myeloid, erythroid, dendritic and T-lymphoid cell progenies. If small percentages of GFP-positive cells are still usually detected in non-B cells, the level of transgene expression remains weak in these populations compared to CD19+ B cells; importantly, GFP-expression intensity differential between B cells and non-B cells is significantly more marked with the EL19 sequence compared to the L19 promoter alone. 26 Residual long terminal repeat promoter activity of self-inactivating lentiviral vectors could also significantly contribute to the unspecific-background GFP expression detected in non-B cells. 40 We further demonstrate that enhanced B-specific recombinant lentiviral vector allows efficient long-term BTK transgene expression in transduced human CD34+ B-cell progeny. In high transduction efficiency conditions, strong and preferential fBTK transgene expression was readily detected in medullar and splenic B cells compared to non-B-cell counterparts, mainly myeloid cells. With limited viral integrations per cell, transgenic BTK protein expression in the B-cell progeny was detected by immunofluorescence. However, using RT-PCR analysis, only low fBTK transgene expression was measured that remains below endogenous level; in addition, B specificity seemed to be absent in these conditions. However, it is likely that fBTK transgene expression was underestimated here, taking into account our global molecular analysis strategy that works on sorted populations that are composed of a mix of transduced and non-transduced cells. Moreover, the observed low B specificity of fBTK transgene expression does not reflect high transcriptional activity of the EL19-fBTK expression cassette in non-B cells, since endogenous BTK level, taken as a reference, is about fourfold lower in latter compared to B cells (data not shown).
BTK is widely expressed in haematopoietic cells, mainly in myeloid and B-lymphoid lineages, but is notably absent from T-lymphoid and plasma cells. 41 BTK is involved in multiple signalling pathways and takes part in regulation of various critical biological processes inside haematopoietic cells, including proliferation, differentiation and apoptosis. 42, 43 In the context of the development of XLA gene therapy, transcriptional targeting of BTK transgene expression to the B-cell compartment thus appears as a rational strategy to avoid unwanted biological effects that could result from ectopic BTK expression. 24 Moreover, since B-cell defect is the main cause of XLA, B-lymphoid-restricted BTK expression should provide full correction of the disease, as already shown with transgenic Xid mice. 27 In this context, transgene expression pattern controlled by our B-specific lentiviral vector is well adapted to XLA gene therapy. First, as demonstrated with GFP, transgene expression begins early at the pro-B-cell stage and remains high and constant from pre-B to circulating mature B cells; strong BTK expression beginning at the pre-B cell stage proved notably important for phenotypic correction in Xid mice. 44 Moreover, the EL19 promoter sequence does not lead to transgene expression in Tlymphoid progeny; transgene expression in plasma cells could not be analysed as such cells do not differentiate in NOD/SCID mice, and CD19-negative terminally differentiated plasma cells are hardly obtained with existing culture systems. 45, 46 Analysis of fBTK transgene expression pattern could not be conducted as precisely as with the GFP transgene; nevertheless, it is unlikely that significant modification of EL19 promoter activity arises from fBTK cDNA substitution in place of the GFP reporter gene.
Until now, therapeutic potential and safety of BTK gene complementation were mainly evaluated in murine models. 24 However, BTK involvement in signalling pathways could vary between humans and mice, as reported for TLR signalling in monocytes 47 and suggested by major differences in XLA and Xid phenotypes. Therefore, the induction of BTK transgenic expression in human cells is the main concern regarding development of XLA gene therapy. Designing XLA gene therapy preclinical studies with human cells currently remains limited by the poor availability of HSC-enriched primary XLA samples and the need for pertinent experimental models. Only one study has reported that the transduction with BTK-expressing vaccinia virus into XLA-derived B-cell lines permits the recovering of BCR-induced Ca 2+ mobilization. 48 X-linked agammaglobulinaemia represents a delicate situation in which the development of gene therapy as an alternative to currently available substitute treatment will necessitate a much improved risk-benefit ratio, Enhanced B-specific lentivector T Moreau et al when compared to most diseases for which it has been attempted, including X-SCID, HIV disease or various forms of cancers. In this context, the achievement of efficiently targeted BTK expression through haematopoietic differentiation to the B-lymphoid lineage with our improved lentiviral vector represents the first step towards this goal. Nevertheless, in the present form of our lentiviral vector, the strong enhancer activity of Emmar still represents a potential risk of random endogenous gene activation through viral genomic integration. In clinical perspectives, further vector development should include the use of insulator sequences to achieve confinement of the enhancer activity. 16 Moreover, the use of tumour-prone animal models could be useful to assess the mutagenic potential of this lentiviral vector.
14 Finally, the development of biological assays and models that would allow evaluation of BTK gene-transfer efficiency and safety directly in human XLA HSC will be critical to progress towards safe XLA gene therapy.
Materials and methods
Primary cells and cell lines
Cord blood and adult BM samples were obtained after individual informed consent for research use from our own institute or external biological resource centre (EFS, Besançon, France). Samples were used as fresh material or after thawing and overnight culture in RPMI, 10% fetal calf serum, 1% penicillin/streptomycin supplemented with DNAseI (100 U ml À1 ; Roche Applied Science, Mannheim, Germany). CD34+ cells were subsequently enriched from CB and BM mononuclear fractions by immuno-selection as previously described. 26 Human haematopoietic cell lines of B-lymphoid (Nalm6, Raji), myeloid (K562, U937) and T-lymphoid (Jurkat subclone, JA16) origins were cultivated in RPMI medium (Cambrex, Viviers, Belgium) with 10% fetal calf serum (Gibco/Invitrogen, Paisley, UK) and 1% penicillin/streptomycin (100 U ml À1 ; Invitrogen). Human 293T epithelial cells were cultivated in Dulbecco's modified Eagle's medium (DMEM; Cambrex) with 10% fetal calf serum and 1% penicillin/streptomycin.
In vitro and in vivo haematopoietic differentiation assays B-lymphoid and myeloid parallel differentiation was performed on murine MS5 stromal cell line as previously described. 26 For dendritic differentiation, 2 Â 10 4 CD34+ cells per well (24-well plate) were cultured for 2 weeks (with 1 4 changeover after 1 week) in RPMI, 1% penicillin/ streptomycin, 10% fetal calf serum, supplemented with human recombinant stem cell factor (20 ng ml À1 a gift from Amgen, Thousand Oaks, CA, USA), granulocyte-macrophage colony-stimulating factor (GM-CSF, 100 ng ml
À1
; Leucomax, Novartis, Rueil Malmaison, France), TNFa (2.5 ng ml À1 ) and Flt3-L (20 ng ml
). The protocol for erythroid differentiation was adapted from Giarratana et al. 
Construction and production of recombinant lentiviral vectors
All lentiviral constructions were derived from the initial self-inactivating lentiviral vector backbone TripDU3-EF1a-GFP (a kind gift of Dr Charneau, Institut Pasteur, Paris, France) 50 that was modified by insertion of the LCD19 promoter sequence (L19) in place of the EF1a ubiquitous promoter as previously described. 26 Original L19-GFP lentiviral vector was next modified by addition of the Emmar murine enhancer sequence at the 5 0 MluI restriction site directly upstream of LCD19 promoter (EL19-GFP vector, Figure 1 ). The Emmar fragment (1023 bp) was generated by PCR from mouse fibroblast genomic DNA (blood quick pure; Macherey Nagel, Hoerdt, France) with the following oligonucleotidic primers (MluI recognition sequences are underlined): Emmar-Fo (5 0 -gttacgcgttagagaggtctggtggagcct) and Em mar-Re (5 0 -gttacgcgtccaaccagcatgttcaactga); correct orientation of Emmar was checked by PCR after cloning of MluI into viral vector. Flag-BTK cDNA (fBTK) was obtained by RT-PCR on total RNA (nucleospin RNAII; Macherey Nagel) from Nalm6 pre-B cell line using FlagBTK-Fo (5 0 -ggatccatggattacaaggacgacgatgacaag gatatcgccgcagtgattctgga, BamHI restriction site is underlined and Flag sequence showed in italics) and BTK-Re (5 0 -ctcgagtcaggattcttcatccatgacatcta, XhoI restriction site is underlined) primers. Generated fragment (2010 bp) was cloned (TA cloning kit; Invitrogen) and sequence integrity (Genome Express, Meylan, France) verified against Ensembl reference BTK sequence (ENST00000308731). The fBTK cDNA was ultimately inserted in place of the GFP gene between BamHI and XhoI restriction sites; lentiviral constructions were subsequently named L19-fBTK and EL19-fBTK according to upstream promoter sequence (Figure 1) . Reliability of regulating and coding regions was finally checked comparatively to reference sequences. targeted cDNA copies) was used for quantification of cDNA samples. PCR specificity was controlled by determining the size of amplicons and checking the absence of fBTK or GFP amplification in non-transduced samples. Ratio of transgenic fBtk relative to endogenous BTK expression was determined by quantification of fBTK and total BTK (transgene+endogenous) cDNA in the same sample. Green fluorescent protein expression was detected by flow cytometry and intensity of expression was quantified by MFI in positive cells: expressed values are normalized MFI that correspond to increasing factor of fluorescence intensity in GFP-positive transduced cells compared to GFP-negative control cells ( ¼ MFI(GFP+)/MFI(GFPÀ)).
Transgenic fBTK protein expression was detected in haematopoietic cell lines by western blot analysis on total protein lysate (10 6 cells) using a rabbit anti-Flag polyclonal antibody (F7425; Sigma Aldrich, St Louis, MO, USA) and secondary anti-rabbit horseradish peroxidasecoupled antibody. fBTK protein was also detected by immunoflurescence (IF) with a mouse anti-Flag monoclonal antibody (clone M2; Sigma Aldrich) and secondary labelling with Alexa Fluor 488-coupled anti-mouse IgG antibody (Invitrogen).
Unexpectedly, intracytoplasmic fBtk protein could neither be detected by flow cytometry, even in highexpressing cell lines, after cell permeabilization and direct labelling with allophycocyanin-coupled monoclonal anti-Flag antibody (surelight allophycocyanin; Perkin Elmer) nor by indirect labelling with primary biotinylated anti-Flag monoclonal antibody (clone M2; Sigma Aldrich) and various fluorescent secondary reagents (allophycocyanin-coupled anti-mouse antibody or streptavidin).
